Olanzapine News and Research

RSS
Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
Dr. Reddy’s Laboratories reports financial results for third-quarter ended December 31, 2009

Dr. Reddy’s Laboratories reports financial results for third-quarter ended December 31, 2009

Majority of doctors appear to ignore FDA warning to screen high-risk medications

Majority of doctors appear to ignore FDA warning to screen high-risk medications

Atypical antipsychotic use for treating elderly patients with dementia decreases

Atypical antipsychotic use for treating elderly patients with dementia decreases

Majority of Medicaid patients on antipsychotic drugs do not undergo metabolic tests, says study

Majority of Medicaid patients on antipsychotic drugs do not undergo metabolic tests, says study

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Antipsychotic medications increase the levels of inflammation markers, find researchers

Antipsychotic medications increase the levels of inflammation markers, find researchers

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

New systematic study for managing treatment-resistant bipolar depression

New systematic study for managing treatment-resistant bipolar depression

Merck update on the status of telcagepant clinical development programs

Merck update on the status of telcagepant clinical development programs

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia

Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

FDA approves Symbyax for treatment-resistant depression

FDA approves Symbyax for treatment-resistant depression

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Study questions use of newer antipsychotic drugs in children

Study questions use of newer antipsychotic drugs in children

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Antipsychotic drugs get FDA label changes

Antipsychotic drugs get FDA label changes